CroíValve is an early stage medical device company who are focused on developing a minimally invasive device for the treatment of tricuspid regurgitation.
The severe cardiac disease affects more than 550,000 people every year in the EU and US. Less than 1% of these usually elderly patients receive surgical treatment, as they are deemed too frail.
The Dublin med-tech start-up joined The Liffey Trust Enterprise Centre in January 2019. Since then they have gone on to raise a record breaking €3.2 million in Angel Investment for its minimally invasive heart treatment device.
The funding will support the continued development of CroíValve’s innovative technology
‘CroíValve was established from a desire to bring a new, safe treatment option that can change and save lives’- CroíValve CEO Dr Lucy O' O'Keeffe